RMTC-03 EVALUATING “BRAIN PERMEABILITY”: A CRITICAL ISSUE FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS TO REDUCE THE INCIDENCE OF BRAIN METASTASES
Stuart Grossman, Amy Barone, Roy Strowd, William Elmquist · 2026
Read RMTC-03 EVALUATING “BRAIN PERMEABILITY”: A CRITICAL ISSUE FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS TO REDUCE THE INCIDENCE OF BRAIN METASTASES by Stuart Grossman, Amy Barone, Roy Strowd, William Elmquist (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13448266.txt.
Description
Grossman and colleagues reported on a 2026 workshop, held with the Adult Brain Tumor Consortium and the Food and Drug Administration, about judging whether drugs truly reach brain tumors. Current tests mostly measure drug levels where tumors light up on scans. Yet much tumor sits in non-enhancing brain, meaning tissue that looks normal on scans, where drug levels often stay too low to work.
Grossman and the workshop group weighed lab models of the blood-brain barrier, spinal fluid sampling, and animal brain studies as ways to judge penetration into non-enhancing tissue. Their main product is a three-level index that sorts candidate drugs as sufficiently permeable, insufficiently permeable, or impermeable for that hidden tissue. Using the index before human efficacy trials could steer funding toward drugs that reach the whole tumor and spare patients toxic treatments with little chance of brain benefit.
Catalog record
| CREATOR | Stuart Grossman, Amy Barone, Roy Strowd, William Elmquist |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |